Concepts (259)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Ketamine | 26 | 2023 | 234 | 10.890 |
Why?
|
| Depressive Disorder, Major | 22 | 2024 | 441 | 7.240 |
Why?
|
| Stress Disorders, Post-Traumatic | 28 | 2023 | 604 | 6.640 |
Why?
|
| Antidepressive Agents | 23 | 2022 | 332 | 5.790 |
Why?
|
| Connectome | 6 | 2023 | 112 | 3.310 |
Why?
|
| Excitatory Amino Acid Antagonists | 10 | 2019 | 151 | 3.190 |
Why?
|
| Glutamic Acid | 10 | 2020 | 309 | 2.520 |
Why?
|
| Brain | 20 | 2024 | 4113 | 2.250 |
Why?
|
| Prefrontal Cortex | 13 | 2023 | 229 | 2.250 |
Why?
|
| Nerve Net | 4 | 2020 | 257 | 1.750 |
Why?
|
| Hippocampus | 13 | 2024 | 915 | 1.700 |
Why?
|
| Military Personnel | 4 | 2023 | 225 | 1.600 |
Why?
|
| Depressive Disorder, Treatment-Resistant | 3 | 2020 | 92 | 1.540 |
Why?
|
| Cerebral Cortex | 5 | 2020 | 621 | 1.470 |
Why?
|
| Stress, Psychological | 11 | 2020 | 1000 | 1.460 |
Why?
|
| Occipital Lobe | 4 | 2014 | 48 | 1.450 |
Why?
|
| Veterans | 8 | 2023 | 1641 | 1.330 |
Why?
|
| Depression | 8 | 2022 | 1715 | 1.090 |
Why?
|
| Synaptic Transmission | 6 | 2020 | 443 | 1.070 |
Why?
|
| Neuronal Plasticity | 3 | 2020 | 304 | 1.070 |
Why?
|
| Schizophrenia | 4 | 2022 | 369 | 1.060 |
Why?
|
| Depressive Disorder | 3 | 2020 | 557 | 1.050 |
Why?
|
| Magnetic Resonance Imaging | 28 | 2024 | 7702 | 1.040 |
Why?
|
| Magnetic Resonance Spectroscopy | 9 | 2024 | 624 | 1.040 |
Why?
|
| Neural Pathways | 4 | 2019 | 298 | 1.000 |
Why?
|
| White Matter | 4 | 2020 | 195 | 0.970 |
Why?
|
| Hallucinogens | 2 | 2022 | 48 | 0.930 |
Why?
|
| Neuroimaging | 9 | 2023 | 403 | 0.910 |
Why?
|
| Aspartic Acid | 6 | 2015 | 126 | 0.890 |
Why?
|
| Riluzole | 2 | 2012 | 22 | 0.860 |
Why?
|
| Anxiety Disorders | 6 | 2017 | 666 | 0.860 |
Why?
|
| Glutamates | 2 | 2023 | 130 | 0.850 |
Why?
|
| Receptors, N-Methyl-D-Aspartate | 3 | 2022 | 259 | 0.750 |
Why?
|
| Neurobiology | 5 | 2020 | 25 | 0.730 |
Why?
|
| gamma-Aminobutyric Acid | 3 | 2016 | 269 | 0.700 |
Why?
|
| Antidepressive Agents, Second-Generation | 2 | 2018 | 56 | 0.680 |
Why?
|
| Psychiatry | 1 | 2023 | 307 | 0.670 |
Why?
|
| Tobacco Use Disorder | 1 | 2021 | 284 | 0.650 |
Why?
|
| Humans | 76 | 2024 | 261506 | 0.650 |
Why?
|
| Secondary Prevention | 1 | 2020 | 329 | 0.640 |
Why?
|
| Nucleus Accumbens | 1 | 2017 | 61 | 0.590 |
Why?
|
| Proton Magnetic Resonance Spectroscopy | 5 | 2024 | 30 | 0.590 |
Why?
|
| Caudate Nucleus | 1 | 2016 | 43 | 0.570 |
Why?
|
| Norepinephrine | 2 | 2018 | 272 | 0.550 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 1 | 2018 | 341 | 0.530 |
Why?
|
| Smoking Cessation | 1 | 2021 | 712 | 0.520 |
Why?
|
| Psychiatric Status Rating Scales | 7 | 2017 | 901 | 0.510 |
Why?
|
| Emotions | 4 | 2024 | 562 | 0.490 |
Why?
|
| Cerebellum | 2 | 2017 | 449 | 0.470 |
Why?
|
| Neurotransmitter Agents | 1 | 2014 | 159 | 0.470 |
Why?
|
| Cognition | 2 | 2019 | 968 | 0.460 |
Why?
|
| Diffusion Tensor Imaging | 6 | 2020 | 303 | 0.450 |
Why?
|
| Pilot Projects | 7 | 2023 | 2803 | 0.450 |
Why?
|
| Anesthetics, Dissociative | 1 | 2012 | 22 | 0.440 |
Why?
|
| Adult | 32 | 2022 | 77950 | 0.430 |
Why?
|
| Schizophrenic Psychology | 2 | 2010 | 102 | 0.430 |
Why?
|
| Anti-Anxiety Agents | 1 | 2012 | 90 | 0.420 |
Why?
|
| Electroconvulsive Therapy | 1 | 2012 | 59 | 0.410 |
Why?
|
| Young Adult | 17 | 2022 | 21445 | 0.410 |
Why?
|
| Borderline Personality Disorder | 1 | 2014 | 151 | 0.400 |
Why?
|
| Male | 41 | 2024 | 123000 | 0.390 |
Why?
|
| Mental Disorders | 2 | 2016 | 862 | 0.380 |
Why?
|
| Brain Mapping | 6 | 2024 | 644 | 0.370 |
Why?
|
| Gap Junctions | 1 | 2010 | 43 | 0.370 |
Why?
|
| Organ Size | 4 | 2021 | 690 | 0.360 |
Why?
|
| Mechanistic Target of Rapamycin Complex 1 | 2 | 2022 | 265 | 0.360 |
Why?
|
| Independent Living | 1 | 2009 | 73 | 0.350 |
Why?
|
| Social Adjustment | 1 | 2009 | 114 | 0.350 |
Why?
|
| Anisotropy | 4 | 2020 | 181 | 0.340 |
Why?
|
| Neurons | 1 | 2019 | 2287 | 0.330 |
Why?
|
| Anesthesia | 1 | 2012 | 296 | 0.330 |
Why?
|
| Double-Blind Method | 3 | 2022 | 2588 | 0.330 |
Why?
|
| Biomarkers | 7 | 2023 | 5047 | 0.320 |
Why?
|
| Female | 35 | 2024 | 141928 | 0.320 |
Why?
|
| Psychotic Disorders | 1 | 2009 | 147 | 0.320 |
Why?
|
| Image Processing, Computer-Assisted | 5 | 2019 | 1648 | 0.310 |
Why?
|
| Mitochondria | 1 | 2014 | 1282 | 0.300 |
Why?
|
| Corpus Callosum | 3 | 2020 | 138 | 0.290 |
Why?
|
| Residence Characteristics | 1 | 2009 | 348 | 0.290 |
Why?
|
| Sirolimus | 2 | 2022 | 814 | 0.280 |
Why?
|
| Middle Aged | 22 | 2022 | 86204 | 0.280 |
Why?
|
| Functional Laterality | 4 | 2017 | 316 | 0.270 |
Why?
|
| Bipolar Disorder | 2 | 2022 | 376 | 0.250 |
Why?
|
| Choline | 3 | 2015 | 76 | 0.250 |
Why?
|
| Treatment Outcome | 8 | 2022 | 32848 | 0.240 |
Why?
|
| Case-Control Studies | 7 | 2022 | 6100 | 0.240 |
Why?
|
| Exposure to Violence | 1 | 2024 | 9 | 0.240 |
Why?
|
| Animals | 17 | 2020 | 59536 | 0.230 |
Why?
|
| Macaca radiata | 6 | 2015 | 19 | 0.230 |
Why?
|
| Suicidal Ideation | 2 | 2023 | 207 | 0.220 |
Why?
|
| Aging | 3 | 2023 | 1582 | 0.220 |
Why?
|
| Amygdala | 3 | 2024 | 127 | 0.210 |
Why?
|
| Self-Injurious Behavior | 1 | 2023 | 54 | 0.210 |
Why?
|
| Combat Disorders | 1 | 2021 | 22 | 0.200 |
Why?
|
| Transcranial Direct Current Stimulation | 1 | 2021 | 20 | 0.200 |
Why?
|
| Smoking | 2 | 2021 | 2440 | 0.200 |
Why?
|
| Habenula | 1 | 2021 | 44 | 0.190 |
Why?
|
| Drugs, Investigational | 1 | 2022 | 135 | 0.190 |
Why?
|
| Functional Neuroimaging | 2 | 2017 | 38 | 0.190 |
Why?
|
| Multicenter Studies as Topic | 2 | 2019 | 543 | 0.190 |
Why?
|
| Habituation, Psychophysiologic | 1 | 2020 | 19 | 0.190 |
Why?
|
| Laburnum | 1 | 2019 | 2 | 0.180 |
Why?
|
| Gyrus Cinguli | 3 | 2017 | 140 | 0.180 |
Why?
|
| Creatine | 3 | 2015 | 61 | 0.180 |
Why?
|
| Benzodiazepines | 2 | 2018 | 170 | 0.180 |
Why?
|
| Cross-Sectional Studies | 5 | 2017 | 4314 | 0.170 |
Why?
|
| Apolipoprotein E4 | 1 | 2019 | 48 | 0.170 |
Why?
|
| Psychotherapy | 1 | 2022 | 247 | 0.170 |
Why?
|
| Adrenergic alpha-1 Receptor Antagonists | 1 | 2018 | 28 | 0.170 |
Why?
|
| Mood Disorders | 3 | 2015 | 163 | 0.170 |
Why?
|
| Cross-Over Studies | 1 | 2020 | 460 | 0.160 |
Why?
|
| Reproducibility of Results | 4 | 2023 | 6009 | 0.160 |
Why?
|
| Locus Coeruleus | 1 | 2018 | 33 | 0.160 |
Why?
|
| Health Surveys | 1 | 2019 | 402 | 0.160 |
Why?
|
| Healthy Volunteers | 1 | 2018 | 187 | 0.150 |
Why?
|
| Adult Survivors of Child Adverse Events | 1 | 2017 | 20 | 0.150 |
Why?
|
| Anxiety | 2 | 2017 | 1179 | 0.150 |
Why?
|
| Resilience, Psychological | 1 | 2018 | 64 | 0.150 |
Why?
|
| Intelligence | 1 | 2017 | 126 | 0.150 |
Why?
|
| Cluster Analysis | 1 | 2019 | 1053 | 0.150 |
Why?
|
| Receptors, Glutamate | 1 | 2016 | 19 | 0.150 |
Why?
|
| Aged | 10 | 2022 | 70117 | 0.150 |
Why?
|
| Hypertrophy | 1 | 2017 | 162 | 0.140 |
Why?
|
| Adolescent | 9 | 2024 | 31252 | 0.140 |
Why?
|
| Models, Neurological | 1 | 2017 | 225 | 0.140 |
Why?
|
| Maternal Deprivation | 2 | 2013 | 15 | 0.140 |
Why?
|
| Infusions, Intravenous | 1 | 2019 | 1382 | 0.140 |
Why?
|
| Sleep Wake Disorders | 1 | 2019 | 348 | 0.140 |
Why?
|
| Adult Survivors of Child Abuse | 1 | 2015 | 17 | 0.140 |
Why?
|
| Suicide, Attempted | 2 | 2023 | 129 | 0.130 |
Why?
|
| Parietal Lobe | 1 | 2015 | 66 | 0.130 |
Why?
|
| Arousal | 1 | 2016 | 120 | 0.130 |
Why?
|
| Internal Capsule | 2 | 2015 | 40 | 0.130 |
Why?
|
| Sex Characteristics | 1 | 2017 | 417 | 0.130 |
Why?
|
| Receptor, Metabotropic Glutamate 5 | 1 | 2014 | 19 | 0.120 |
Why?
|
| Chronic Disease | 1 | 2020 | 1819 | 0.120 |
Why?
|
| Citric Acid Cycle | 1 | 2014 | 86 | 0.120 |
Why?
|
| Cognitive Dysfunction | 1 | 2019 | 333 | 0.120 |
Why?
|
| Saliva | 1 | 2015 | 231 | 0.120 |
Why?
|
| Hydrocortisone | 1 | 2015 | 388 | 0.120 |
Why?
|
| Gray Matter | 1 | 2014 | 63 | 0.120 |
Why?
|
| Corticotropin-Releasing Hormone | 2 | 2011 | 82 | 0.120 |
Why?
|
| Obsessive-Compulsive Disorder | 1 | 2021 | 622 | 0.120 |
Why?
|
| Polymorphism, Genetic | 1 | 2019 | 1450 | 0.120 |
Why?
|
| Serotonin Plasma Membrane Transport Proteins | 2 | 2011 | 51 | 0.120 |
Why?
|
| Carbon Isotopes | 1 | 2014 | 333 | 0.120 |
Why?
|
| Corticosterone | 1 | 2013 | 119 | 0.110 |
Why?
|
| Thiopental | 1 | 2012 | 7 | 0.110 |
Why?
|
| Sensory Gating | 1 | 2012 | 14 | 0.110 |
Why?
|
| Receptor, Adenosine A2A | 1 | 2012 | 27 | 0.110 |
Why?
|
| Energy Metabolism | 1 | 2018 | 992 | 0.110 |
Why?
|
| Protons | 1 | 2014 | 473 | 0.100 |
Why?
|
| Longitudinal Studies | 1 | 2017 | 1945 | 0.100 |
Why?
|
| Research Design | 1 | 2019 | 1544 | 0.100 |
Why?
|
| Electroencephalography | 2 | 2012 | 898 | 0.100 |
Why?
|
| Wounds and Injuries | 1 | 2015 | 399 | 0.100 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2019 | 4938 | 0.100 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2019 | 2594 | 0.100 |
Why?
|
| Hypnotics and Sedatives | 1 | 2012 | 218 | 0.100 |
Why?
|
| Cohort Studies | 3 | 2019 | 9244 | 0.090 |
Why?
|
| Overweight | 1 | 2014 | 484 | 0.090 |
Why?
|
| Social Desirability | 1 | 2009 | 22 | 0.090 |
Why?
|
| Mental Status Schedule | 1 | 2009 | 60 | 0.090 |
Why?
|
| Disease Models, Animal | 3 | 2018 | 7222 | 0.090 |
Why?
|
| Dyskinesia, Drug-Induced | 1 | 2009 | 46 | 0.090 |
Why?
|
| Urban Population | 1 | 2010 | 269 | 0.080 |
Why?
|
| Peer Group | 1 | 2009 | 133 | 0.080 |
Why?
|
| Social Environment | 1 | 2009 | 176 | 0.080 |
Why?
|
| Psychotropic Drugs | 1 | 2009 | 133 | 0.080 |
Why?
|
| Antipsychotic Agents | 1 | 2012 | 414 | 0.080 |
Why?
|
| Metabolic Syndrome | 1 | 2011 | 353 | 0.080 |
Why?
|
| Fear | 2 | 2024 | 254 | 0.070 |
Why?
|
| Activities of Daily Living | 1 | 2009 | 552 | 0.070 |
Why?
|
| Seizures | 1 | 2012 | 989 | 0.070 |
Why?
|
| Animals, Newborn | 1 | 2010 | 1338 | 0.070 |
Why?
|
| Up-Regulation | 1 | 2012 | 2450 | 0.070 |
Why?
|
| Predictive Value of Tests | 1 | 2014 | 4892 | 0.070 |
Why?
|
| Models, Biological | 1 | 2014 | 3254 | 0.070 |
Why?
|
| Socioeconomic Factors | 1 | 2009 | 1225 | 0.070 |
Why?
|
| Combined Modality Therapy | 2 | 2015 | 8865 | 0.060 |
Why?
|
| Obesity | 1 | 2016 | 2884 | 0.060 |
Why?
|
| Facial Expression | 1 | 2024 | 49 | 0.060 |
Why?
|
| Severity of Illness Index | 1 | 2014 | 4320 | 0.060 |
Why?
|
| United States | 2 | 2019 | 15433 | 0.060 |
Why?
|
| Psychometrics | 2 | 2023 | 937 | 0.060 |
Why?
|
| Linear Models | 2 | 2017 | 1085 | 0.050 |
Why?
|
| Administration, Intravenous | 1 | 2022 | 249 | 0.050 |
Why?
|
| Maternal Behavior | 2 | 2010 | 62 | 0.050 |
Why?
|
| Positron-Emission Tomography | 2 | 2022 | 2173 | 0.040 |
Why?
|
| Machine Learning | 1 | 2021 | 319 | 0.040 |
Why?
|
| Temporal Lobe | 1 | 2020 | 192 | 0.040 |
Why?
|
| Executive Function | 1 | 2019 | 160 | 0.040 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2023 | 5539 | 0.040 |
Why?
|
| Lateral Ventricles | 1 | 2017 | 26 | 0.040 |
Why?
|
| Hypothalamo-Hypophyseal System | 1 | 2018 | 127 | 0.040 |
Why?
|
| Aged, 80 and over | 3 | 2022 | 29902 | 0.040 |
Why?
|
| Corpus Striatum | 1 | 2017 | 104 | 0.040 |
Why?
|
| Sympathetic Nervous System | 1 | 2018 | 159 | 0.040 |
Why?
|
| Thalamus | 1 | 2017 | 132 | 0.040 |
Why?
|
| Meta-Analysis as Topic | 1 | 2017 | 276 | 0.040 |
Why?
|
| Analysis of Variance | 2 | 2011 | 2307 | 0.030 |
Why?
|
| Motion | 1 | 2016 | 193 | 0.030 |
Why?
|
| Risk Factors | 2 | 2023 | 17523 | 0.030 |
Why?
|
| Self Report | 1 | 2019 | 756 | 0.030 |
Why?
|
| Radioimmunoassay | 1 | 2015 | 191 | 0.030 |
Why?
|
| Drug Design | 1 | 2017 | 375 | 0.030 |
Why?
|
| Mental Processes | 1 | 2014 | 53 | 0.030 |
Why?
|
| Carbon Radioisotopes | 1 | 2014 | 116 | 0.030 |
Why?
|
| Eating | 1 | 2016 | 421 | 0.030 |
Why?
|
| Inflammation | 1 | 2023 | 2522 | 0.030 |
Why?
|
| Oximes | 1 | 2014 | 175 | 0.030 |
Why?
|
| Alleles | 1 | 2019 | 2437 | 0.030 |
Why?
|
| Symptom Assessment | 1 | 2015 | 267 | 0.030 |
Why?
|
| Quetiapine Fumarate | 1 | 2012 | 16 | 0.030 |
Why?
|
| Dibenzothiazepines | 1 | 2012 | 13 | 0.030 |
Why?
|
| Aripiprazole | 1 | 2012 | 22 | 0.030 |
Why?
|
| Genotype | 2 | 2011 | 4109 | 0.030 |
Why?
|
| Evoked Potentials, Auditory | 1 | 2012 | 50 | 0.030 |
Why?
|
| Oxygen | 1 | 2016 | 754 | 0.030 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2016 | 592 | 0.030 |
Why?
|
| Acoustic Stimulation | 1 | 2012 | 118 | 0.030 |
Why?
|
| Risperidone | 1 | 2012 | 62 | 0.030 |
Why?
|
| Auditory Cortex | 1 | 2012 | 38 | 0.030 |
Why?
|
| Prognosis | 1 | 2009 | 21713 | 0.030 |
Why?
|
| Reaction Time | 1 | 2012 | 234 | 0.030 |
Why?
|
| Quinolones | 1 | 2012 | 160 | 0.020 |
Why?
|
| Heart Rate | 1 | 2014 | 737 | 0.020 |
Why?
|
| Child | 2 | 2022 | 29154 | 0.020 |
Why?
|
| Nesting Behavior | 1 | 2010 | 14 | 0.020 |
Why?
|
| Housing, Animal | 1 | 2010 | 38 | 0.020 |
Why?
|
| Texas | 1 | 2021 | 6311 | 0.020 |
Why?
|
| New York | 1 | 2010 | 104 | 0.020 |
Why?
|
| Neuropsychological Tests | 1 | 2014 | 1178 | 0.020 |
Why?
|
| Spectrum Analysis | 1 | 2010 | 139 | 0.020 |
Why?
|
| Life Change Events | 1 | 2010 | 83 | 0.020 |
Why?
|
| Object Attachment | 1 | 2010 | 58 | 0.020 |
Why?
|
| Genomics | 1 | 2020 | 2738 | 0.020 |
Why?
|
| Personality Inventory | 1 | 2010 | 178 | 0.020 |
Why?
|
| Radiopharmaceuticals | 1 | 2014 | 1301 | 0.020 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2013 | 2063 | 0.020 |
Why?
|
| Down-Regulation | 1 | 2014 | 2074 | 0.020 |
Why?
|
| Macaca mulatta | 1 | 2010 | 717 | 0.020 |
Why?
|
| Blood Pressure | 1 | 2014 | 1467 | 0.020 |
Why?
|
| Gene Frequency | 1 | 2011 | 1163 | 0.020 |
Why?
|
| Behavior, Animal | 1 | 2011 | 709 | 0.020 |
Why?
|
| Pyridines | 1 | 2014 | 1244 | 0.020 |
Why?
|
| Age Factors | 1 | 2016 | 5377 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2010 | 1546 | 0.020 |
Why?
|
| Blood Glucose | 1 | 2011 | 1244 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2014 | 4971 | 0.020 |
Why?
|
| Insulin | 1 | 2011 | 1454 | 0.020 |
Why?
|
| Rats | 1 | 2013 | 6086 | 0.020 |
Why?
|
| Feeding Behavior | 1 | 2010 | 808 | 0.020 |
Why?
|
| Phenotype | 1 | 2015 | 6295 | 0.010 |
Why?
|
| Surveys and Questionnaires | 1 | 2015 | 5687 | 0.010 |
Why?
|
| Piperazines | 1 | 2012 | 2101 | 0.010 |
Why?
|
| Recurrence | 1 | 2010 | 4758 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2017 | 11965 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2010 | 6869 | 0.010 |
Why?
|